JP2007508353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508353A5 JP2007508353A5 JP2006534713A JP2006534713A JP2007508353A5 JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5 JP 2006534713 A JP2006534713 A JP 2006534713A JP 2006534713 A JP2006534713 A JP 2006534713A JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- pharmaceutical composition
- cationic liposome
- paclitaxel
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000002502 liposome Substances 0.000 claims 13
- 125000002091 cationic group Chemical group 0.000 claims 12
- -1 cationic lipid Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 229930012538 Paclitaxel Natural products 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 8
- 229960001592 paclitaxel Drugs 0.000 claims 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 6
- 230000007935 neutral effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 3
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010020843 Hyperthermia Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000002482 anti-endothelial effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000036031 hyperthermia Effects 0.000 claims 2
- 238000009217 hyperthermia therapy Methods 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03023539.4 | 2003-10-15 | ||
| EP03023539 | 2003-10-15 | ||
| EP04000361.8 | 2004-01-09 | ||
| EP04000361 | 2004-01-09 | ||
| PCT/EP2004/011655 WO2005039533A1 (en) | 2003-10-15 | 2004-10-15 | Method of administering cationic liposomes comprising an active drug |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012159071A Division JP2012229255A (ja) | 2003-10-15 | 2012-07-17 | 活性成分を含有するカチオンリポソームの投与方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007508353A JP2007508353A (ja) | 2007-04-05 |
| JP2007508353A5 true JP2007508353A5 (enExample) | 2007-12-06 |
| JP5645340B2 JP5645340B2 (ja) | 2014-12-24 |
Family
ID=34524705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534713A Expired - Fee Related JP5645340B2 (ja) | 2003-10-15 | 2004-10-15 | 活性成分を含有するカチオンリポソームの投与方法 |
| JP2012159071A Pending JP2012229255A (ja) | 2003-10-15 | 2012-07-17 | 活性成分を含有するカチオンリポソームの投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012159071A Pending JP2012229255A (ja) | 2003-10-15 | 2012-07-17 | 活性成分を含有するカチオンリポソームの投与方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080063699A1 (enExample) |
| EP (2) | EP1673069B1 (enExample) |
| JP (2) | JP5645340B2 (enExample) |
| AU (1) | AU2004283464B8 (enExample) |
| CA (1) | CA2542217C (enExample) |
| DK (1) | DK2286794T3 (enExample) |
| ES (1) | ES2574231T3 (enExample) |
| HU (1) | HUE028648T2 (enExample) |
| PL (1) | PL2286794T3 (enExample) |
| PT (1) | PT2286794T (enExample) |
| WO (1) | WO2005039533A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
| EP1853250B1 (en) | 2005-02-18 | 2011-11-02 | Abraxis BioScience, LLC | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2006243337B2 (en) | 2005-05-04 | 2011-09-29 | Syncore Biotechnology Co., Ltd | Method of administering a cationic liposomal preparation comprising paclitaxel |
| CA2616515C (en) * | 2005-09-01 | 2014-09-23 | Biolipox Ab | Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| KR100658436B1 (ko) * | 2005-12-09 | 2006-12-27 | 한국화학연구원 | 아데노실코발라민 함유 피부질환 치료용 외용제 조성물 |
| ES2609388T3 (es) * | 2006-03-22 | 2017-04-20 | Syncore Biotechnology Co., Ltd | Tratamiento del cáncer de mama triple negativo a receptores |
| WO2007134819A1 (en) * | 2006-05-18 | 2007-11-29 | Medigene Ag | Cationic liposomal preparations for the treatment of rheumatoid arthritis |
| KR20190109593A (ko) | 2010-03-29 | 2019-09-25 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| ES2600912T3 (es) | 2010-03-29 | 2017-02-13 | Abraxis Bioscience, Llc | Métodos para tratar el cáncer |
| EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| KR20180049180A (ko) | 2010-06-04 | 2018-05-10 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| WO2012016048A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti- viral azide-containing compounds |
| US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
| JP6112512B2 (ja) * | 2010-12-01 | 2017-04-12 | レクシ ファーマ インコーポレイテッド | 難治性癌を治療するための方法 |
| HRP20230443T1 (hr) | 2011-05-24 | 2023-09-15 | BioNTech SE | Individualizirana cjepiva protiv raka |
| SG11201404361UA (en) | 2012-01-26 | 2014-09-26 | Life Technologies Corp | Methods for increasing the infectivity of viruses |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| AU2013351542B2 (en) | 2012-11-28 | 2018-08-09 | BioNTech SE | Individualized vaccines for cancer |
| DE102013009744A1 (de) * | 2013-03-26 | 2014-10-02 | Forschungszentrum Jülich GmbH | Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| EP3838264A1 (en) | 2015-06-04 | 2021-06-23 | Crititech, Inc. | Taxane particles and their use |
| HK1254909A1 (zh) | 2015-09-16 | 2019-08-02 | Dfb Soria, Llc | 药物纳米粒子的传送及其使用方法 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| ES2858092T3 (es) | 2016-04-04 | 2021-09-29 | Crititech Inc | Formulaciones para el tratamiento de tumores sólidos |
| NZ753214A (en) * | 2016-11-11 | 2022-02-25 | Univ Western Health Sciences | Methods of treating upper tract urothelial carcinomas |
| TWI852903B (zh) * | 2017-01-05 | 2024-08-21 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| EP3595633B1 (en) | 2017-03-15 | 2023-07-05 | DFB Soria, LLC | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
| ES2980123T3 (es) | 2017-06-09 | 2024-09-30 | Crititech Inc | Composiciones para uso en el tratamiento de quistes epiteliales mediante inyección intraquística de partículas antineoplásicas |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| KR102303762B1 (ko) | 2017-06-14 | 2021-09-23 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
| AU2018345652A1 (en) | 2017-10-03 | 2020-03-19 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
| CA3092500A1 (en) | 2018-03-16 | 2019-09-19 | Dfb Soria, Llc | Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes |
| AU2024214679A1 (en) * | 2023-01-31 | 2025-08-14 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Use of paclitaxel cationic liposome in treating tumors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254135B (it) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica. |
| AU3922193A (en) * | 1992-03-23 | 1993-10-21 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
| DE4447770C2 (de) * | 1994-08-20 | 2002-12-19 | Max Delbrueck Centrum | Verfahren zur Herstellung von liposomal verkapseltem Taxol |
| US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| US7314637B1 (en) * | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| CN1235567C (zh) * | 1999-09-09 | 2006-01-11 | 加利福尼亚大学董事会 | 将紫杉烷输送到正在生成的血管的阳离子性脂质体 |
| UY27185A1 (es) * | 2001-02-28 | 2002-09-30 | Bristol Myers Squibb Co | Dosificación metronómica de taxanos |
| JP4975964B2 (ja) * | 2002-06-26 | 2012-07-11 | メディゲーネ アクチエンゲゼルシャフト | 脂肪親和性化合物から成る陽イオン性リポソームの製法 |
| ATE490763T1 (de) * | 2002-06-26 | 2010-12-15 | Medigene Ag | Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem |
-
2004
- 2004-10-15 PT PT101807501T patent/PT2286794T/pt unknown
- 2004-10-15 EP EP04790494.1A patent/EP1673069B1/en not_active Expired - Lifetime
- 2004-10-15 JP JP2006534713A patent/JP5645340B2/ja not_active Expired - Fee Related
- 2004-10-15 CA CA2542217A patent/CA2542217C/en not_active Expired - Lifetime
- 2004-10-15 ES ES10180750.1T patent/ES2574231T3/es not_active Expired - Lifetime
- 2004-10-15 EP EP10180750.1A patent/EP2286794B8/en not_active Expired - Lifetime
- 2004-10-15 DK DK10180750.1T patent/DK2286794T3/en active
- 2004-10-15 US US10/575,779 patent/US20080063699A1/en not_active Abandoned
- 2004-10-15 AU AU2004283464A patent/AU2004283464B8/en not_active Ceased
- 2004-10-15 PL PL10180750.1T patent/PL2286794T3/pl unknown
- 2004-10-15 WO PCT/EP2004/011655 patent/WO2005039533A1/en not_active Ceased
- 2004-10-15 HU HUE10180750A patent/HUE028648T2/en unknown
-
2012
- 2012-07-17 JP JP2012159071A patent/JP2012229255A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007508353A5 (enExample) | ||
| JP5704788B2 (ja) | 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ | |
| JP2018528184A5 (enExample) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| CA2412795A1 (en) | Improved liposomal camptothecins and uses thereof | |
| JP2011144190A (ja) | 抗癌剤の効果増強剤 | |
| Wu et al. | Nanoparticle-based combination therapy for ovarian cancer | |
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| TWI539957B (zh) | 偏亞砷酸鈉於治療白血病及淋巴瘤之用途 | |
| JP2003528920A (ja) | 血管損傷性活性を有する併用療法 | |
| JP2010043115A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| JP2008540364A5 (enExample) | ||
| CN101687104A (zh) | 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| Garattini et al. | Perspectives in cancer chemotherapy | |
| O'Shaughnessy et al. | Current status of paclitaxel in the treatment of breast cancer | |
| CA2483826A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| CN101652138A (zh) | 1-取代芳基-2（1h）-吡啶酮化合物的新医药用途 | |
| Tralongo et al. | Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience | |
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| JP2006523664A5 (enExample) | ||
| Qu et al. | Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report | |
| Kuo et al. | Functionalized drug-gene delivery materials to transport inhibitor of apoptosis protein antagonists for tumor malignancy management | |
| CN113993515B (zh) | 使用藏红花酸治疗实体肿瘤的方法 | |
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents |